{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:34:11Z","timestamp":1778319251026,"version":"3.51.4"},"reference-count":31,"publisher":"Mattioli1885","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: The number of elderly psoriasis patients is increasing, yet data on biological treatments in this population remains limited. Objectives: To evaluate the characteristics, efficacy, and safety of biologics in psoriasis patients aged \u226565 years and identify factors contributing to treatment interruption or discontinuation. Methods: The study included psoriasis patients aged \u226565 years who had received at least one biological treatment at a tertiary center for a minimum of 24 weeks between 2022 and 2024. Demographic and clinical data, treatment history, PASI scores, adverse events, and reasons for treatment interruption or discontinuation were evaluated. Results: Among 231 patients on biologics, 43 (18.6%) were aged \u226565 years (mean age: 70.2 \u00b1 4.8 years, male-to-female ratio: 2:1). Mean PASI scores improved from 14.5 \u00b1 8.8 at baseline to 1.5 \u00b1 1.5 at weeks 12\u201316, and to 0.83 \u00b1 1.2 at week 52. Latent tuberculosis and anti-HBc positivity were common (65.1% and 51.2%, respectively), but no reactivation occurred. Adverse events were reported in 39.5% of patients, most commonly infections (27.9%). Treatment-ending events occurred in 7.0%, all due to malignancies. Treatment interruptions occurred in 20.9%, mainly due to noncompliance, transportation difficulties, and comorbidities. Notably, 20.9% of the patients required assistance to attend their hospital visits, and 44.2% required help administering their drug. Treatment was discontinued in 16.3%, primarily due to malignancies and secondary failure. Conclusions: Biologics are effective in psoriasis patients aged \u226565 years. A relatively high malignancy rate emphasizes the importance of age-appropriate screening. Noncompliance, comorbidities, transportation problems, and healthcare access barriers may pose challenges in long-term treatment maintenance.<\/jats:p>","DOI":"10.5826\/dpc.1601a5995","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:39:48Z","timestamp":1769787588000},"page":"5995","source":"Crossref","is-referenced-by-count":1,"title":["Biologic Treatment in Elderly Patients with Psoriasis: Focus on Safety and Adherence"],"prefix":"10.5826","volume":"16","author":[{"given":"Gizem","family":"Pehlivan Uluta\u015f","sequence":"first","affiliation":[{"name":"Haseki Training and Research Hospital, Department of Dermatology and Venereology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu\u011fba","family":"\u00d6zk\u00f6k Akbulut","sequence":"first","affiliation":[{"name":"Liv Hospital Ulus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"10.5826\/dpc.1601a5995_ref1","doi-asserted-by":"crossref","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. DOI:10.1136\/bmj.m1590. PMID: 32467098","DOI":"10.1136\/bmj.m1590"},{"key":"10.5826\/dpc.1601a5995_ref2","doi-asserted-by":"crossref","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021;157(8):940-946. DOI:10.1001\/jamadermatol.2021.2007. PMID: 34190957","DOI":"10.1001\/jamadermatol.2021.2007"},{"key":"10.5826\/dpc.1601a5995_ref3","doi-asserted-by":"crossref","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8:743180. DOI:10.3389\/fmed.2021.743180. PMID: 34977058","DOI":"10.3389\/fmed.2021.743180"},{"key":"10.5826\/dpc.1601a5995_ref4","doi-asserted-by":"crossref","unstructured":"Liao YH, Chen KH, Tseng MP, Sun CC. Pattern of skin diseases in a geriatric patient group in Taiwan: a 7-year survey from the outpatient clinic of a university medical center. Dermatology. 2001;203(4):308-313. DOI:10.1159\/000051778. PMID: 11752818","DOI":"10.1159\/000051778"},{"key":"10.5826\/dpc.1601a5995_ref5","doi-asserted-by":"crossref","unstructured":"Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review. J Cutan Med Surg. 2020;24(2):174-186. DOI:10.1177\/1203475419897578. PMID: 31950853","DOI":"10.1177\/1203475419897578"},{"key":"10.5826\/dpc.1601a5995_ref6","doi-asserted-by":"crossref","unstructured":"Kostovi\u0107 K, \u017du\u017eul K, \u010ceovi\u0107 R, Bukvi\u0107 Mokos Z. Psoriasis in the mature patient: Therapeutic approach in the era of biologics. Clin Dermatol. 2018;36(2):222-230. DOI:10.1016\/j.clindermatol.2017.10.013. PMID: 29566926","DOI":"10.1016\/j.clindermatol.2017.10.013"},{"key":"10.5826\/dpc.1601a5995_ref7","doi-asserted-by":"crossref","unstructured":"van Winden MEC, ter Haar ELM, Groenewoud HMM, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK. Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups. Acta Derm Venereol. 2020;100(14):adv00215. DOI:10.2340\/00015555-3569. PMID: 32556353","DOI":"10.2340\/00015555-3569"},{"key":"10.5826\/dpc.1601a5995_ref8","doi-asserted-by":"crossref","unstructured":"Bukvi\u0107 Mokos Z, Jovi\u0107 A, \u010ceovi\u0107 R, Kostovi\u0107 K, Mokos I, Marinovi\u0107 B. Therapeutic challenges in the mature patient. Clin Dermatol. 2018;36(2):128-139. DOI:10.1016\/j.clindermatol.2017.10.004. PMID: 29566917","DOI":"10.1016\/j.clindermatol.2017.10.004"},{"key":"10.5826\/dpc.1601a5995_ref9","doi-asserted-by":"crossref","unstructured":"Ter Haar ELM, van den Reek JMPA, Sadat Chenarani Moghadam M, et al. Frailty and functional dependency in a multicenter cohort of older adults with psoriasis: Prevalence and extent of and implications for psoriasis management. J Am Acad Dermatol. 2024;91(6):1289-1293. DOI:10.1016\/j.jaad.2024.07.1527 PMID: 39245362","DOI":"10.1016\/j.jaad.2024.07.1527"},{"key":"10.5826\/dpc.1601a5995_ref10","doi-asserted-by":"crossref","unstructured":"Liu Z, Liang Q, Ren Y, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8(1):200. DOI:10.1038\/s41392-023-01451-2. PMID: 37179335","DOI":"10.1038\/s41392-023-01451-2"},{"key":"10.5826\/dpc.1601a5995_ref11","doi-asserted-by":"crossref","unstructured":"Garcia-Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463-470. DOI:10.1001\/archdermatol.2011.2768. PMID: 22508869","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"10.5826\/dpc.1601a5995_ref12","doi-asserted-by":"crossref","unstructured":"Bakirtzi K, Sotiriou E, Papadimitriou I, et al. Elderly patients with psoriasis: long-term efficacy and safety of modern treatments. J Dermatolog Treat. 2022;33(3):1339-1342. DOI:10.1080\/09546634.2020.1809623. PMID: 32783678","DOI":"10.1080\/09546634.2020.1809623"},{"key":"10.5826\/dpc.1601a5995_ref13","doi-asserted-by":"crossref","unstructured":"Momose M, Asahina A, Hayashi M, Yanaba K, Umezawa Y, Nakagawa H. Biologic treatments for elderly patients with psoriasis. J Dermatol. 2017;44(9):1020-1023. DOI:10.1111\/1346-8138.13853. PMID: 28439956","DOI":"10.1111\/1346-8138.13853"},{"key":"10.5826\/dpc.1601a5995_ref14","doi-asserted-by":"crossref","unstructured":"Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41(11):974-980. DOI:10.1111\/1346-8138.12653. PMID: 25346301","DOI":"10.1111\/1346-8138.12653"},{"key":"10.5826\/dpc.1601a5995_ref15","doi-asserted-by":"crossref","unstructured":"Medina C, Carretero G, Ferrandiz C, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29(5):858-864. DOI:10.1111\/jdv.12688. PMID: 25185962","DOI":"10.1111\/jdv.12688"},{"key":"10.5826\/dpc.1601a5995_ref16","doi-asserted-by":"crossref","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561-567. DOI:10.1111\/ced.14979. PMID: 34642965","DOI":"10.1111\/ced.14979"},{"key":"10.5826\/dpc.1601a5995_ref17","doi-asserted-by":"crossref","unstructured":"Phan C, Beneton N, Delaunay J, et al. Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis. Acta Derm Venereol. 2020;100(18):adv00316. DOI:10.2340\/00015555-3678. PMID: 33111960","DOI":"10.2340\/00015555-3678"},{"key":"10.5826\/dpc.1601a5995_ref18","doi-asserted-by":"crossref","unstructured":"Ricceri F, Bardazzi F, Chiricozzi A, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2019;33(1):143-146. DOI:10.1111\/jdv.15139. PMID: 29906311","DOI":"10.1111\/jdv.15139"},{"key":"10.5826\/dpc.1601a5995_ref19","doi-asserted-by":"crossref","unstructured":"Ohata C, Anezaki H, Yanase T, et al. Real-world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study. J Dermatol. 2024;51(12):1634-1640. DOI:10.1111\/1346-8138.17385. PMID: 39031284","DOI":"10.1111\/1346-8138.17385"},{"key":"10.5826\/dpc.1601a5995_ref20","doi-asserted-by":"crossref","unstructured":"Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019. DOI:10.1111\/j.1365-2133.2009.09505.x. PMID: 19857207","DOI":"10.1111\/j.1365-2133.2009.09505.x"},{"key":"10.5826\/dpc.1601a5995_ref21","doi-asserted-by":"crossref","unstructured":"Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293-297. DOI:10.2340\/00015555-1719. PMID: 24158307","DOI":"10.2340\/00015555-1719"},{"key":"10.5826\/dpc.1601a5995_ref22","doi-asserted-by":"crossref","unstructured":"Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173-1179. DOI:10.1001\/jamadermatol.2013.5015. PMID: 23925466","DOI":"10.1001\/jamadermatol.2013.5015"},{"key":"10.5826\/dpc.1601a5995_ref23","doi-asserted-by":"crossref","unstructured":"Chiricozzi A, Pavlidis A, Dattola A, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65. Expert Opin Drug Saf. 2016;15(11):1459-1462. DOI:10.1080\/14740338.2016.1226279. PMID: 27534970","DOI":"10.1080\/14740338.2016.1226279"},{"key":"10.5826\/dpc.1601a5995_ref24","doi-asserted-by":"crossref","unstructured":"Naci Emecen A, K\u0131ran P, \u00c7a\u011flayan D. Influential Factors of Tuberculosis Notification Rates in Turkey: A Provincial-Level Spatial Analysis. Thorac Res Pract. 2024;25(2):68-74. DOI:10.5152\/ThoracResPract.2024.23109. PMID: 38454202","DOI":"10.5152\/ThoracResPract.2024.23109"},{"key":"10.5826\/dpc.1601a5995_ref25","doi-asserted-by":"crossref","unstructured":"Koo T, Baek G, Jue MS. Risk of tuberculosis infection and serial changes in interferon-gamma release assays in elderly patients with psoriasis receiving biologic therapy. J Dermatol. 2022;49(9):887-894. DOI:10.1111\/1346-8138.16471. PMID: 35619545","DOI":"10.1111\/1346-8138.16471"},{"key":"10.5826\/dpc.1601a5995_ref26","doi-asserted-by":"crossref","unstructured":"K\u00f6rber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies. Drugs Aging. 2018;35(2):135-144. DOI:10.1007\/s40266-018-0520-z. PMID: 29404966","DOI":"10.1007\/s40266-018-0520-z"},{"key":"10.5826\/dpc.1601a5995_ref27","doi-asserted-by":"crossref","unstructured":"Militello G, Xia A, Stevens SR, Van Voorhees AS. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55(3):517-519. DOI:10.1016\/j.jaad.2006.02.010. PMID: 16908365","DOI":"10.1016\/j.jaad.2006.02.010"},{"key":"10.5826\/dpc.1601a5995_ref28","unstructured":"Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis. J Drugs Dermatol. 2015;14(8):846-852. PMID: 26267729."},{"key":"10.5826\/dpc.1601a5995_ref29","doi-asserted-by":"crossref","unstructured":"Van De Kerkhof PC, De Hoop D, De Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200(4):292-8. DOI: 10.1159\/000018390. PMID: 10894958","DOI":"10.1159\/000018390"},{"key":"10.5826\/dpc.1601a5995_ref30","doi-asserted-by":"crossref","unstructured":"Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408-14. DOI: 10.1001\/archderm.140.4.408. PMID: 15096368","DOI":"10.1001\/archderm.140.4.408"},{"key":"10.5826\/dpc.1601a5995_ref31","doi-asserted-by":"crossref","unstructured":"Chan SA, Hussain F, Lawson LG, et al. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat. 2013;24(1):64-9. DOI: 10.3109\/09546634.2011.607425. PMID: 21797808","DOI":"10.3109\/09546634.2011.607425"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/5995\/3747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/5995\/3746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:00:55Z","timestamp":1770044455000},"score":1,"resource":{"primary":{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/view\/5995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1601a5995","relation":{"has-manifestation":[{"id-type":"other","id":"1-82-5995-g3746","asserted-by":"subject"},{"id-type":"other","id":"1-82-5995-g3747","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1601a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"23"}}